The abstract is read at the publisher; the summary is JClub's.
Amivantamab shows dose-dependent NK cell–mediated cytotoxicity against diffuse pleural mesothelioma cells, linked to EGFR and MET engagement and receptor internalization.
- Why it matters: Diffuse pleural mesothelioma has no approved tumor-directed therapies, and EGFR/MET co-expression suggests a rationale for bispecific targeting plus immune activation.
- What they did: The study profiled EGFR and MET in DPM patient cohorts and cell lines using transcriptomics, single-cell RNA-seq, immunohistochemistry, and biochemical assays, then tested amivantamab in PBMC/NK co-cultures and in patient-derived xenografts in immunodeficient mice reconstituted with human NK cells.
- The result: Amivantamab inhibited ligand-induced EGFR/MET signaling, promoted receptor internalization, and induced NK cell–dependent antibody-dependent cellular cytotoxicity in vitro, while reducing tumor growth in multiple mesothelioma patient-derived xenograft models without overt toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.